Malignant Neoplasm of Stomach Recruiting Phase 2 Trials for Capecitabine (DB01101)

Also known as: Cancer, Gastric / Gastric Malignancies / Stomach Cancer / Gastric Cancers / Gastric Cancer / Gastric malignancy / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02205047Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction AdenocarcinomaTreatment
NCT03448835Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)Treatment
NCT04034251Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal CarcinomatosisTreatment
NCT02954536Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerTreatment
NCT04065282The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.Treatment
NCT04250948Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric CancerTreatment
NCT02931890Multicentric Randomised Trial for Resectable Gastric CancerTreatment
NCT03161522Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric CancerTreatment
NCT03817411Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ CancerTreatment
NCT01665274Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric CancerTreatment
NCT02250209T- XELOX in HER2-positive Stage III Gastric Cancer After D2 GastrectomyTreatment